A share price of Stoke Therapeutics Inc [STOK] is currently trading at $12.81, up 12.07%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The STOK shares have gain 8.84% over the last week, with a monthly amount drifted -2.21%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, TD Cowen upgraded its rating to Outperform on March 26, 2024. TD Cowen downgraded its rating to a Market Perform. BofA Securities upgraded its rating to a Neutral and raised its price target to $12 on May 01, 2023. In a note dated January 06, 2023, BofA Securities downgraded an Underperform rating on this stock and revised its target price from $22 to $9.
Stoke Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $3.78 and $17.58. Currently, Wall Street analysts expect the stock to reach $26.5 within the next 12 months. Stoke Therapeutics Inc [NASDAQ: STOK] shares were valued at $12.81 at the most recent close of the market. An investor can expect a potential return of 106.87% based on the average STOK price forecast.
Analyzing the STOK fundamentals
Trailing Twelve Months sales for Stoke Therapeutics Inc [NASDAQ:STOK] were 16.74M which represents 47.94% growth. Gross Profit Margin for this corporation currently stands at 0.73% with Operating Profit Margin at -7.01%, Pretax Profit Margin comes in at -6.3%, and Net Profit Margin reading is -6.3%. To continue investigating profitability, this company’s Return on Assets is posted at -0.36, Equity is -0.54 and Total Capital is -0.48.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.91 points at the first support level, and at 11.00 for the second support level. However, for the 1st resistance point, the stock is sitting at 13.61, and for the 2nd resistance point, it is at 14.40.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Stoke Therapeutics Inc [NASDAQ:STOK] is 5.09. Also, the Quick Ratio is 5.09, while the Cash Ratio stands at 3.01. Considering the valuation of this stock, the price to sales ratio is 40.53, the price to book ratio is 2.92.
Transactions by insiders
Recent insider trading involved Ticho Barry, CHIEF MEDICAL OFFICER, that happened on Dec 02 ’24 when 10000.0 shares were sold. CHIEF MEDICAL OFFICER, Ticho Barry completed a deal on Nov 01 ’24 to sell 10000.0 shares. Meanwhile, Officer BARUCH TICHO bought 20000.0 shares on Nov 01 ’24.
